← FDA DRUG APPROVALS

FDA ANDA · ANDA201408

GUANFACINE EXTENDED-RELEASE

guanfacine

Sponsor: TWI PHARMS

APPLICATION
ANDA201408
TYPE
ANDA
ORIGINAL APPROVAL
2015-06-02
LATEST ACTION
2025-02-12
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

GUANFACINE HYDROCHLORIDEPrescription
GUANFACINE HYDROCHLORIDE EQ 3MG BASE · TABLET, EXTENDED RELEASE · ORAL
GUANFACINE HYDROCHLORIDEPrescription
GUANFACINE HYDROCHLORIDE EQ 1MG BASE · TABLET, EXTENDED RELEASE · ORAL
GUANFACINE HYDROCHLORIDEPrescription
GUANFACINE HYDROCHLORIDE EQ 4MG BASE · TABLET, EXTENDED RELEASE · ORAL
GUANFACINE HYDROCHLORIDEPrescription
GUANFACINE HYDROCHLORIDE EQ 2MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2025-02-12Labeling · Supplement 12 · standardAP
2019-07-30Labeling · Supplement 8 · standardAP
2019-07-30Labeling · Supplement 4 · standardAP
2019-07-30Labeling · Supplement 5 · standardAP
2015-06-02UNKNOWN · OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →